American Parkinson Disease Association Welcomes Two Accomplished Leaders to National Board of Directors

New Board Members Bring Deep Expertise in Health Equity, Policy, and Nonprofit Leadership to APDA NEW YORK, NY, JUNE...see more 10, 2025 — The American Parkinson Disease Association (APDA) is proud to announce the appointment of two distinguished professionals to its National Board of Directors: J. Zoë Beckerman, JD, MPH and Adalynn E. Harris, PhD, MPH, […]

Read More

American Parkinson Disease Association Kicks Off 2025 Optimism Walk Series

Across the country, local communities will mobilize in the fight against Parkinson’s. NEW YORK, NEW YORK, APRIL 7, 2025...see more – The American Parkinson Disease Association (APDA) is pleased to announce the schedule for the 2025 APDA Optimism Walk series – a nationwide movement to raise awareness and vital funds for the Parkinson’s disease (PD) community. […]

Read More

American Parkinson Disease Association to Educate and Empower During Parkinson’s Disease Awareness Month

APDA helps the Parkinson’s community live life to the fullest in April and year-round. With a diagnosis every six...see more minutes, public awareness and support are crucial. NEW YORK, NY, MARCH 11, 2025 – April is Parkinson’s Disease Awareness Month, and the American Parkinson Disease Association (APDA) will commemorate the month with a “Did You Know?” […]

Read More

FDA Approves New Adaptive DBS System

In exciting news, the FDA approved Medtronic’s deep brain stimulation (DBS) system known...see more as BrainSense™. Unlike standard DBS, which delivers electricity to the brain at pre-programmed settings, this technology can sense the brain’s electric signals, known as local field potentials or LFPs, and adjust the stimulation accordingly. This capability, […]

Read More

ONAPGO: A Newly-Approved Medication for OFF Periods in Parkinson’s

ONAPGOTM: A Newly-Approved Medication for OFF Periods in Parkinson’s Breaking News! The first subcutaneous (under the skin) apomorphine infusion,...see more now called ONAPGOTM, was approved by the Food and Drug Administration (FDA) on February 4, 2025. Apomorphine is a dopamine agonist whose effects have a rapid onset. It has been available in the US as a […]

Read More